DAWN 250516 5.00C(DAWN250516C5000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

DAWN250516C5000

Watchlist

0.00
0.000.00%

15min DelayTrading Apr 24 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data From Its Phase 2 DAWN Trial of Laru-zova in Patients With X-linked Retinitis Pigmentosa (XLRP)
PR NewswireApr 24 08:00 ET
BofA Securities Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $21
Moomoo NewsApr 17 14:32 ET · Ratings
Day One Biopharmaceuticals Price Target Lowered to $21 From $24 at BofA
TipRanksApr 17 08:46 ET
Day One Biopharmaceuticals Drops To US$7.22, Yet Insiders May Have Sold Too Early
Simply Wall StApr 5 08:10 ET
H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $36
Moomoo NewsApr 3 15:32 ET · Ratings
Day One Biopharm Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Dow JonesApr 3 06:53 ET · Ratings

Comments

ApexTradeZ

Dec 26, 2024 00:20

What’s the Top Undervalued BioTech

$Humacyte (HUMA.US)$ $uniQure NV (QURE.US)$ $Aquestive Therapeutics (AQST.US)$ $IDEAYA Biosciences (IDYA.US)$ $Day One Biopharmaceuticals (DAWN.US)$
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you

IDKWTFIMDOING

Jul 26, 2024 02:43

$Day One Biopharmaceuticals (DAWN.US)$
https://www.tipranks.com/news/blurbs/strong-buy-rating-for-day-one-biopharmaceuticals-amid-strategic-partnership-and-promising-financial-health?futusource=news_stock_stockpagenews&ns_stock_id=80620831336770&src=2&utm_medium=referral&utm_source=moomoo.com&client_hour_clock=24&clientlang=2

Trytosaveabit

Jul 25, 2024 15:47

$Day One Biopharmaceuticals (DAWN.US)$ Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib
Benzinga· 01:54
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indications
OJEMDA (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II tria...

MARKET-TEST-DUMMY

Jun 20, 2024 04:39

turn around

$Day One Biopharmaceuticals (DAWN.US)$ we gonna see retraisement back to 18?

Trytosaveabit

Jun 12, 2024 19:34

Update

$XOMA Corp (XOMA.US)$ $Day One Biopharmaceuticals (DAWN.US)$ XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of Its Priority Review Voucher